Over the past 30 years the mitochondrial permeability transition -the permeabilization of the inner mitochondrial membrane due to the opening of a wide pore -has progressed from being considered a curious artifact induced in isolated mitochondria by Ca 2+ and phosphate to a key cell-death-inducing process in several major pathologies. Its relevance is by now universally acknowledged and a pharmacology targeting the phenomenon is being developed. The molecular nature of the pore remains to this day uncertain, but progress has recently been made with the identification of the F O F 1 ATP synthase as the probable proteic substrate. Researchers sharing this conviction are however divided into two camps: these believing that only the ATP synthase dimers or oligomers can form the pore, presumably in the contact region between monomers, and those who consider that the ring-forming c subunits in the F O sector actually constitute the walls of the pore. The latest development is the emergence of a new candidate: Spastic Paraplegia 7 (SPG7), a mitochondrial AAA-type membrane protease which forms a 6-stave barrel. This review summarizes recent developments of research on the pathophysiological relevance and on the molecular nature of the mitochondrial permeability transition pore. This article is part of a Special Issue entitled: Mitochondrial Channels edited by Jean-Claude Martinou.
Introduction
The enduring saga of the mitochondrial permeability transition (mPT) may be -respectfully -likened to great literary opuses such as Mahābhārata or the Divine Comedy. In those admirable -and lengthypoems the tale keeps evolving, from one parvan or canto to the next, through complexities, asides, coups-de-theatre, cameos, philosophical/ religious considerations. Sections of both poems narrate the ascent of a symbolical mountain towards transcendency and perfection. Researchers in the mPT field are still climbing, following different paths full of detours and obstacles, knowing they may end up in some ravine or selva oscura but hoping they will eventually reach the summit. Their most recent efforts and opinions have been summarized in a number of reviews [1] [2] [3] [4] [5] [6] [7] [8] [9] documenting the transition from "traditional" to "new" molecular models of the mitochondrial permeability transition pore (mPTP). While the focus is currently on its identity, it has long been operationally defined on the basis of its phenomenology and characteristics. Very briefly put, it can be defined as the permeabilization of the inner mitochondrial membrane (IMM) to solutes up to 1.5 kDa, due to the opening of a large pore formed by a protein complex. Several lines of evidence actually indicate that the pore can exist in multiple sizes (or conductance states) (e.g. [10] ). mPTP opening is facilitated by mitochondrial Ca 2+ overload, oxidative stress, IMM depolarization and other factors (for detailed reviews see e.g. [11] [12] [13] [14] [15] [16] . It is famously inhibited not only by cyclosporin A (CsA), a cyclic undecapeptide which acts by binding cyclophilin D (CypD), universally considered to be a regulatory component of the mammalian mPTP complex [5, 17] , but also by Mg
2+
, ADP, ATP, low pH values. Pore opening is reversible on both a short (ms) and a long (seconds) time scale, as shown directly by electrophysiological observation ( [11] , and refs. therein) as well as indirectly by monitoring mitochondrial polarization and tracer fluxes [18] [19] [20] .
The mPTP has been proposed to function in the cell's everyday life as a Ca 2+ release channel allowing the rapid discharge of excess Ca 2+ taken up by mitochondria [21] . While this may well be the case (but see [22] ), the enduring interest surrounding the mPT is certainly due to the role it plays in multiple pathologies. IMM permeabilisation results in a "bioenergetic catastrophe": the mitochondrial transmembrane electrochemical proton gradient is dissipated, ATP synthesis stops, respiratory substrates and nucleotides are lost from the mitochondrial matrix. If mPTP opening is widespread and sustained, it causes cell death, whose exact features and classification may depend on circumstances (see below). Various insults and stresses can in fact cause this "dysfunction", which has become a pharmacological target. We thus first briefly review these aspects, and then discuss the currently hot topic of the molecular nature of the mPTP. A comprehensive overview of all aspects of research on the mitochondrial permeability transition would be far beyond the scope of a paper for this special issue. We thus intend it mainly as an update for the interested reader, and apologize a priori for being often schematic and for the many omissions.
Pathological relevance
The classification of mPT-induced cell death as necrosis or apoptosis has been debated. The dilemma seems now to have been superseded by the realization that a whole spectrum of cell death modalities exists [23, 24] , with varieties of "programmed necrosis" and "necroptosis" [25] [26] [27] occupying the middle ground between the extremes, and the mPTP involved in several (e.g. [28] [29] [30] [31] . One process that may deserve special mention in this context is autophagy, in which the mPTP has a longrecognized role (e.g. (revs): [28, 32] ). We now briefly discuss the part played by the mPT in some major pathologies.
Ischemia/reperfusion injury
The responsibilities of the mPT in reperfusion injury were ascertained more than 20 years ago [33] [34] [35] [36] . Extensive literature surveys can be found in, e.g., [4, 6, 31, 37] . Pore opening takes place when, at reperfusion, inducing factors take the upper hand. These include a return of pH to higher values, the possibility by re-energized mitochondria to take up the increased Ca 2+ of the cytosol (an uptake under acute challenge conditions, mediated by the mitochondrial calcium uniporter (MCU): [38, 39] ), and the intense generation of reactive oxygen species (ROS) as oxygen is again available (Fig. 1) . The mechanism accounting for this last, important, event has been clarified recently [40] . In agreement with this concept, inhibitors of the mPTP (see Table 1 ) such as CsA [36, [41] [42] [43] , [MeAla 6 ]cyclosporin [44] , Sanghliferin [41, 45] , NIM811 [46] , Debio-025 [47] , are protective in experimental systems and also apparently in humans ( [31] and refs therein; but see [48] ). Most studies have focused on cardiac I/R. The involvement of the mPTP in damage sustained upon infarction of other organs has been less studied, but it is presumably just as relevant (e.g.: stroke: [49, 50] ; damages in skeletal muscle and kidney after I/R of the lower limb: [51] ). The mPTP has also been attributed a key role in cardioprotection afforded by pre-, post-, remote and chemical conditioning (note however the doubts generated by recent clinical studies on the outcome of these procedures in humans: [52] [53] [54] ). The complex signaling cascades activated by these maneuvers have been defined in considerable detail (revs.: [13, [55] [56] [57] [58] ), and the major ones have been proposed to converge on the inhibition of Glycogen synthase kinase-3 ß (GSK3ß), which has a well-recognized activating role on the mPTP [59] [60] [61] [62] [63] [64] (Fig. 1) .
Signaling is initiated by the ischemia-induced release of cell membrane receptor ligands ("autacoids") such as adenosine (generated by the breakdown of ATP) [65] [66] [67] [68] , bradykinin (which induces production of ROS and NO) (e.g. [69] [70] [71] ), endogenous opioids (endorphins, dynorphins, enkephalins; exogenous opioids such as morphine are also effective) [72] [73] [74] . There appears to be considerable cross-talk between these receptors [75] [76] [77] , whose engagement results in the activation of a set of kinases known as RISK (reperfusion injury salvage kinases), including Akt, Erk1/2, PKG, PKC-ε and p70s6K. These kinases can also be activated by ROS, either directly or through inhibition of redox-sensitive phosphatases, or, in the case of PKG and possibly also of PKC-ε [78] , via NO, whose production is increased due to Aktmediated upregulation of eNOS [79] [80] [81] in complexes which also comprise phosphorylated PKA [82] . By activating the Akt/eNOS pathway ischemic preconditioning (and postconditioning: [83] ) results in Snitrosylation of a number of mitochondrial proteins, a modification thought to protect sensitive sites from subsequent ROS-induced oxidation [84, 85] . These include CypD, which can be nitrosylated at cysteines 103, 156 and 203 [5] (Fig. 1 ; see also Section 3.1). The RIS kinases perform an inactivating phosphorylation on GSK3ß, which is constitutively active and phosphorylates, among other substrates, CypD, favoring its interaction with the mPTP complex [13] . This action may be mediated by the assembly of mitochondria-targeted signaling complexes in caveolin-enriched vesicles [86] [87] [88] [89] [90] [91] [92] . Activation of Akt alone is insufficient [93] . A recent study [94] suggests that the assembly of these "signalosomes" is PKA-dependent, and it is promoted by preconditioning via inhibition of a phosphodiesterase. Kinases, including Akt [13] , PKCε [87] and PKA [95] may also act on the mPTP by direct phosphorylation of mitochondrial proteins. A cardioprotective role is attributed to hydrogen sulfide (H 2 S) which also acts on the Akt/GSK3ß axis [81] . In this case ischemia causes a decrease of endogenous H 2 S production, which can be antagonized by preconditioning protocols. Exogenous H 2 S donors are well-recognized agents of "chemical preconditioning" (e.g.: [96] [97] [98] ) (see Table 1 ). A recent paper [99] has proposed that mitochondrial calpain, activated by matrix [Ca 2+ ] increase, contributes to the onset of the mPT after I/R. The study utilized swelling of isolated heart mitochondria as a mPT readout: swelling was partially inhibited by calpeptin (a calpain inhibitor) and almost completely, as expected, by CsA, suggesting that calpain action contributed to mPTP activation. Interestingly, the ND6 subunit of respiratory chain complex I was cleaved, and complex I inactivated. ROS production was not studied. A patch-clamp study [100] has found no significant direct effect of calpain or calpeptin on the mPTP. Another regulatory pathway of relevance in I/R has been proposed to involve CypD acetylation/deacetylation [101] . CypD acetylation (at Lys166), reversed by mitochondrial deacetylase SIRT3 [102, 103] , favors CypD interaction with mPTP complex components and thus the mPT (as well as Bax/Bak-dependent apoptosis: [104] ). SIRT3 downregulation sensitizes mitochondria to mPTP opening, and SIRT3-mediated deacetylation of CypD is reported to be enhanced downstream of postconditioning [101] . Interestingly, Verma et al. [105] have reported that knock-down of SIRT4, another mitochondrial isoform which lacks deacetylase activity but has ADPribosyltransferase activity, has the opposite effect, i.e., it increases resistance to mPTP induction. Postconditioning and remote (and remote-post) conditioning also have the mPTP as a major end target and largely use the same signaling pathways to prevent its opening (e.g.: [55, 56, 69, 81, [106] [107] [108] [109] [110] (Fig. 1) .
The translation of the accumulated biochemical knowledge into clinical practice has now begun, and various pharmacological interventions targeting aspects of the processes leading to necrotic cell death are under consideration (see Table 1 ) (e.g. [81, [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] ; revs.: [31, 120, [128] [129] [130] ).
Neurodegeneration
The mPT is believed to be a major pathway to cell death in assorted degenerative diseases of the nervous system, downstream of alterations in Ca 2+ and redox homeostasis (revs.: [6, [131] [132] [133] [134] ). The p66Shc- mediated diversion of reducing equivalents from reduced cyt C to ROS production [135] and hence mPT induction has been emphasized in this context [136] [137] [138] as well as in that of stroke [139] . Pharmacological tools are being developed in hopes of at least slowing the progress of these pathologies (Table 1 ) (e.g. [140] [141] [142] [143] [144] [145] [146] [147] [148] ; rev.: [128, 149] ). Many natural products are found to antagonize mPT onset as a result of their antioxidant action (e.g. [150, 151] ; rev: [149] ). Whether this may translate into some level of efficacy in vivo remains in most cases to be investigated. Natural redox-active compounds, such as polyphenols, have the frustrating characteristic of being capable of acting either as antioxidants, in particular if challenged with independently produced oxidant species, or as pro-oxidants, through chain autooxidation reactions which are favoured by elevated concentrations and the presence of initiating agents [152] [153] [154] [155] .
Cancer
While an increased occurrence, or facilitation, of the mPT results in accentuated cell death and organ degeneration, its suppression conversely favors the onset, growth and propagation of cancer (revs.: [1, 6, 13, [156] [157] [158] [159] ). In analogy to what happens in preconditioning, signaling through the Akt-GSK3β-CypD axis leads to desensitization. An important, although complex and still largely unclear, role is also assigned to Tumour necrosis factor receptor-associated protein-1 (TRAP-1) (rev.: [160, 161] ), a chaperone present in the mitochondria, upregulated in many cancer cells. TRAP-1 acts as an anti-oxidant, interacts with and opposes the mPT-promoting function of CypD [162] and acts on mitochondrial c-Src kinase [163] and on succinate dehydrogenase [164, 165] . Its upregulation apparently results in repression of mPT-mediated cell death and promotion of the switch of cancerous mitochondria from aerobic respiration to glycolysis (the Warburg effect) (revs.: [161, 166] ). TRAP-1 and the mPTP are thus two of the several possible targets of mitochondria-directed antineoplastic agents (mitocans) (revs.: [156, [167] [168] [169] ). Mostly in vitro studies have identified a number of mPT inducers (see Table 1 ) ( [157, [170] [171] [172] [173] [174] [175] [176] [177] [178] [179] [180] [181] [182] [183] ; rev.: [184] ).
Ullrich congenital muscular dystrophy (UCMD) and Bethlem myopathy (BM) (collagen VI-related)
Dystrophies caused by alterations of collagen VI, an extracellular matrix component, present a range of clinical manifestations (e.g. [185] ), depending on just what the molecular alteration is, with Ullrich dystrophy being the most severe and Bethlem myopathy a relatively benign form. Rather surprisingly, mitochondrial dysfunction resulting in an enhanced propensity to undergo the mPT turned out to be a key factor in the aetiogenesis of these disorders: the threshold for mPT induction appears to be lower in diseased cells than in normal ones ( [186] [187] [188] [189] [190] ; revs.: [191] [192] [193] ). Mitochondria in melanocytes from Duchenne dystrophy patients were also found to be affected by a latent dysfunction [194, 195] , suggesting a common signaling pathway linking cell-extra cellular matrix interactions and mitochondrial functionality. The details of this signaling pathway remain to be worked out, but they include oxidative stress caused by an increased mono amine oxidase (MAO) activity [196, 197] . The key, upstream factor in the pathology is a pronounced impairment of autophagy, i.e. a suboptimal elimination of defective mitochondria which therefore remain in situ intoxicating the cells [198] [199] [200] [201] . In agreement with the involvement of the mPTP, genetic elimination of CypD prevented myofiber degeneration in Col6a1(−/−) mice [189] , and CsA and non-immunosuppressive analogs acting on the mPTP rescued at least partially the dystrophic phenotype in biopsies, cultured myocytes [186, 187] , mouse [202] [203] [204] and zebrafish [204, 205] models and in patients in pilot clinical trials [206, 207] . Positive effects were also observed upon administration of Debio-025, a non-immunosuppressive cyclophilin inhibitor, to a mouse model of Duchenne dystrophy [208, 209] . N-(3-Chloro-2-methylphenyl)-5-(4-fluoro-3-hydroxyphenyl)isoxazole-3-carboxamide, a recently developed mPTP inhibitor, was also able to improve motor functions in a zebrafish collagen VI myopathic model [210] (Table 1) .
Molecular composition
This key sub-field of mPT research has been very active in recent years. The 1990s had seen the emergence of a model envisioning mPTP formation by a complex comprising cyclophilin D as a detachable regulatory subunit, the adenine nucleotide translocator (ANT) or another tripartite carrier of the IMM, the voltage-dependent anion channel (VDAC) and the translocator protein (TSPO) as outer membrane components (revs., e.g.: [6, 11, 34, [211] [212] [213] ). The notion was based on abundant circumstantial evidence, including protein-protein interaction studies, pharmacological effects, electrophysiological recordings. Yet the model was picked apart piecemeal by genetic manipulations. Kokoszka et al. [214] began by showing that the mPT could still take place in mouse liver mitochondria lacking ANT1 and ANT2. This negated that the pore was formed by the ANT, a conclusion supported by a characterization of mPTP channel activity in the presence of high concentrations of atractyloside, a powerful and selective ANT inhibitor, which turned out to have no effect [215] . To accommodate the evidence for its involvement the ANT is nowadays considered to be a modulator, i.e., a component of a complex formed by several proteins one -or some, but not the ANT -of which form the pore proper. Baines and coworkers later showed that the phosphate carrier (PiC) was also not a core component, although in its absence the mPT occurred less readily [216, 217] . Bernardi's and Molkentin's groups demonstrated that VDAC isoforms were dispensable as well [218, 219] , as confirmed by electrophysiological studies [220] . Conditional elimination of the TSPO did not alter the characteristics of the mPTP, thus confuting earlier pharmacological evidence of its involvement [221] . These "negative" results lent appeal to alternative models. Electrophysiology of the IMM suggests that the mPTP has a binary structure (e.g. [222] ). In planar bilayer experiments reconstituted pore-forming components of the protein import machinery of the mitochondrial inner membrane, Tim23 [223] and Tim22 [224, 225] , known to exist as dimers [225, 226] , formed channels with relatively similar properties, including the high conductance, and behavior (for a detailed discussion see, e.g., [6, 227] ). Another possibility put forward was the "maxi chloride channel", molecularly unidentified but observed in many studies on the plasma membrane [215, 220] . While these candidacies remain valid, currently opinion polls definitely point to other proteins, discussed in Sections 3.1-3.4.
Cyclophilin D
The only component to survive genetic scrutiny was CypD [228] [229] [230] , which has been confirmed again and again in its role as a modulator of the pore's propensity to open in mammals. In fact, all attempts to identify the core, channel-forming component of the mPTP have relied on the identification of CypD-interacting proteins. Binding to the ANT was reported by Crompton's and Halestrap's groups in 1998 [231, 232] . Interaction with PiC was also shown and confirmed [216, 233] . The idea that the ATPase may form the mPTP originated from the observation that CypD interacted with the lateral stalk (the Oligomycin Sensitivity Conferring Protein, OSCP) of the complex [234] . Spastic Paraplegia Protein 7 (SPG7) emerged as the top candidate from a proteomics study because it could be co-immunoprecipitated with CypD [235] (see Section 3.4). Cyclophilin D (revs., e.g.: [236, 237] ) however is a peptidyl prolyl cis-trans isomerase (PPIase), i.e. a chaperone which may well be expected to have several "customers", some possibly related and some presumably unrelated to mPTP formation or regulation. The "partners" recognized so far are listed in recent reviews [238, 239] and include GSK3ß, ERK and TRAP-1. The matter is complicated by the existence of a pool of CypD outside the mitochondrial matrix [238] . Furthermore CypD is now known to be subjected to post-translational modifications (revs.: [5, 238] ). Besides undergoing acetylation/deacetylation (see Section 2.1, and note that some ATP synthase subunits, including the OSCP, are also modified by acetylation and can be deacetylated by SIRT3 [240] ), it is phosphorylated by mitochondrial redoxsensitive GSK3ß (in turn modulated by mtERK in at least some cancerous cells), resulting in mPT facilitation [157, 241] . Cysteine 203 of CypD can be S-nitrosylated: the modification represses mPT induction by oxidative stress, thus pointing to a crucial role of Cys203 in the process [242] and in preconditioning (see Section 2.1).
Whether the PPIase activity of CypD (which is inhibited by CsA) is involved in its pro-mPTP action is unclear. In early work the potencies of cyclosporins A, G and H as inhibitors of PPIase activity were reported to correlate with their effectiveness as inhibitors of the mPTP [243] , suggesting that was the case. This conceptual approach was extended to six cyclosporin derivatives by Nicolli et al. [244] , who reached much the same conclusion. The opposite one was suggested by a study [245] showing that CsA-sensitive mPT was induced by diethylpyrocarbonate (DPC), which inhibited instead CypD PPIase activity (measured on a test peptide). The effect on mPTP activity was thus attributed essentially to CypD binding to the core component(s). This view is implicit in the model proposed by Bernardi's group whereby inhibition of mPT upon CsA-induced detachment of CypD is due to phosphate binding to a site normally masked by the interacting CypD ( [246, 247] ; see however [248] ). Detachment of the isomerase, with the obvious consequent loss of any activity on its binding partner, is not by itself sufficient for mPTP downregulation. CypD binding itself (at least to the ANT) also seems not to require PPIase activity [45, 249] . Halestrap's group has studied Sanglifehrin A, which also inhibits the mPT and the PPIase activity of CypD, but does not cause detachment of CypD from the ANT or PiC. This would seem to suggest that PPIase activity is needed for mPT induction, provided of course that the ANT and/or PiC are relevant CypD binding partners in this context (reviewed in [4] ). A comparison of mPTP gating patterns in CypD + and CypD -mouse mitoplasts showed that
CypD only influences the probability of activity onset, not the characteristics of the channel's gating on a fast time scale once it has started to operate [230] . This would seem to suggest that the action of CypD may consist in a discrete initial event, more easily identifiable in an isomerization than in a binding step under the relevant experimental conditions. On the other hand, CsA does inhibit mPTP activity as observed in patch-clamp experiments when CypD is (presumably) present [250] . A reasonable conclusion may be that both the presence of CypD and its PPIase activity facilitate (but are not necessary for) the onset of mPTP activity. Once activated by an initial event, the pore continues to operate until some other event determines its inactivation. It should be noted that pore activity can be observed also in the geneticallyinduced absence of CypD and presence of Pi [229, 230] , indicating that Pi binding to a CypD-masked site is not an efficient inhibitory mechanism in this system, which may have subtly adapted to the absence of the PPIase. Given the pathophysiological relevance of the mPTP, and its peculiarity of being the only agreed-upon component of the complex, CypD obviously is a major pharmacological target (revs.: [251, 252] ). Mice lacking its gene show not only various protective phenotypes [209, 228, [253] [254] [255] [256] [257] [258] [259] , but also metabolic alterations, cardiac hypertrophy, reduction in cardiac function, and rapid onset of heart failure under stressful conditions [260, 261] . Besides CsA, its mitochondria-targeted variant [146, 147] , and its derivatives such as blood-brain-barrier (BBB)-permeant NIM811 [262] , Debio-025 [263] , N-methyl-4-valinecyclosporin A [15, 244] , N-methyl-4-isoleucine-cyclosporin A (Cs29) [264] , and the macrolide Sanglifehrin [45] have been considered and used in trials and/or preclinical work (Table 1) . Other cyclosporin derivatives have been synthetized and assessed for binding to other cyclophilin isoforms [265] . Some quinoxaline derivatives were found to bind to and inhibit CypD and CypA in the μM concentration range [266] , but have found scarce application. Other small molecules have been identified as candidates in in silico work [267] . The availability of the crystallographic structure of CypD [265, 268, 269] ought to help in finding new effective CypD-targeted drugs.
Carriers and supercomplexes
After the demonstration that the expression of ANT and PiC is not mandatory for the mPT these proteins have obviously faded away, yet the accumulated evidence that they have something to do with the phenomenon remains. They are now widely considered to act as regulators, with modalities and through interactions at present still largely obscure. Given the strong candidacy of the ATP synthase to the role of poreforming "subunit" of the mPTP complex, a logical hypothesis is that regulation may occur within the so-called "ATP synthasome" (see, e.g., [4] ). This is a supramolecular complex comprising these carriers, the ATP synthase complex and possibly other proteins (e.g. hexokinase 2 (HK2)) [270] [271] [272] . Electron microscopy images of the isolated supercomplex were interpreted as showing the two carriers occupying positions adjacent to the F O sector (c subunit ring) of the ATPase [271] , as is to be expected also in situ for transmembrane proteins. The details of these interactions (if they actually occur in the native environment, which is doubted e.g. by Bernardi and coworkers [1] ) need to be worked out before we understand how, for example, binding of atractyloside to the ANT can translate into opening of a cryptic pore formed by the ATP synthase. Halestrap and Richardson [4] have suggested a possible mediation by cardiolipin, which may be an important determinant of supercomplex formation [273] and is tightly bound by PiC [274] , ANT [275, 276] and ATP synthase [277, 278] . The oligomerization of this latter complex has been reported to be influenced by cardiolipin [279] , and an interaction of cardiolipin with the c subunit of F O has been confirmed by solid state NMR studies with bacterial proteins [280] . Cardiolipin can alter the function of the proteins it binds to; a striking example is provided by its interaction with cytochrome c, which it turns into a peroxidase (rev.: [281] ). It may also be worth mentioning in this context that supercomplexes involving the ATP synthase and complexes of the respiratory chain (the "respirasomes") (revs.: [282] [283] [284] ) are known to form and to be stabilized by cardiolipin [285] . The association with complex I ( [286, 287] ; but see [288] for apparently discrepant observations) may be of particular interest in view of the influence exerted by complex I on mPTP activity [247, 289, 290] .
ATP synthase
Mitochondrial complex V, the ATP synthase (rev.: [291] ), currently is the front runner in the marathon towards the eventual identification of the mPTP. In retrospect, it is hard to explain why it was not considered as a plausible candidate until recently: it was well appreciated that the mPTP might coincide with a mitochondrial protein of major importance, since it had not been eliminated by evolution. We had actually considered the possibility in the early '90s, but at the time the ANT seemed too strong a candidate to mount a challenge. More attention ought perhaps to have been given to the reports that a phosphorylated peptide related to the c subunit of the ATPase F O sector was dephosphorylated under conditions leading to the mPT, and dephosphorylation was inhibited by CsA [292] [293] [294] . Another consideration we may make here is that our work has suggested that the mPTP channel (or rather its "half") may be the same specie as the plasma membrane "maxi-chloride channel" whose identity is unknown [220] . It is by now widely accepted that the F O F 1 ATPase is ectopically expressed in the plasma membrane of many cell types (e.g. [295] [296] [297] [298] [299] ), and it is thought it may have there essentially the same subunit organization as the mitochondrial complex, its presence being due in fact to migration from mitochondria [300, 301] , so that the possibility exists that it may be the molecular substrate of both the maxi-chloride channel and the mPTP. It might be relevant in this context that the plasma membrane F O F 1 complex was only observed as a monomer [301] , since currently researchers proposing that mPTP = ATPase can be classified into two major camps: those hypothesizing that the mPTP forms at the interface between ATP synthase dimers or perhaps tetramers, and those arguing instead that it arises from the c-ring of the F O sector (Fig. 2A) . Both points of view are supported by experimental results, but have some (still) weak points.
mPTP formation by dimers of the F O F 1 ATP synthase
The case for this model has been eloquently made in a recent review [1] and can only be summarized here. As mentioned, ATPase candidacy followed from the observation ( [234, 302] ; see also [9, 303] ) that CypD interacts with the OSCP subunit of the peripheral stalk (on ATPase structure, e.g.: [1, 291, [304] [305] [306] [307] ; on ATP synthase pharmacology: [308, 309] ). The next step was the realization that the CypD binding site coincided with that of Bz-423, an ATPase inhibitor and, as it turned out, apoptosis and mPT inducer. Furthermore, Bernardi's group observed that the calcium retention capacity (CRC) of mammalian and yeast mitochondria depended on whether the ATP synthase complexes were synthesising or hydrolysing ATP, with a higher CRC, i.e. a lower propensity to mPTP induction, in the hydrolytic mode [302, 310] . In eukaryotes the mitochondrial ATPase complexes are organized in dimers and higherorder oligomers (e.g.: [287, 288, [311] [312] [313] [314] ). The monomomer units interact via their F O sectors; subunits a, e, and g are the major ones involved in mammals (for a discussion see [1, 314] ). Atomic force microscopy studies have indicated that the distance between two monomers in a dimer varies depending on whether ATP synthesis or hydrolysis is taking place [315] , which was taken as a clue that mPTP opening may have to do with modifications in the interaction of the two monomer units (which appear to move closer when hydrolysing). Planar bilayer experiments then showed that exposure of the phospholipid membrane to ATPase dimers (isolated by blue native gel electrophoresis), but not to ATPase monomers, resulted in ion conduction by large pores resembling those associated with mPTP activity [302] . The distribution of conductance steps was actually closer to that of a "half-PTP" channel [220] , suggesting that the maximum-size mPTP may be formed by ATPase tetramers [1] . Bernardi [317, 318] . This substitution results in an impaired proton pumping, while ATP hydrolysis still takes place [319] .
The most stringent approach to the verification of the molecular identity of the mPTP is no doubt genetic, i.e. establishing correlations between genetic alterations (mutations, deletions) in candidate proteins and mPTP characteristics. As a first step in this direction Bernardi , thiol oxidants, Mg 2+ and a nonhydrolyzable ATP analog, and are thus considered to represent the Drosophila version of mPTP. In yeast, a CsA-insensitive permeability pore was described nearly 20 years ago [322] ; its study in situ requires that Ca 2+ uptake be provided for with an ionophore [323] , since yeast mitochondria do not readily take up this ion. The yeast Ca
2+
-sensitive pore shares some other properties with mammalian mPTP (sensitization by oxidative stress, inhibition by Mg 2+ /ADP) although it differs in other respects [321] . Saccharomyces cerevisiae ATP synthase dimers in bilayers also produce pores, with a conductance intermediate between those observed for Drosophila and for mammals. Interestingly, mutants lacking the e and g subunits, involved in dimer formation, turned out to be resistant to IMM permeabilization, supporting the dimer model [321] .
In this context, the report that a CsA-sensitive permeability transition takes place also in Rho0 mitochondria (in an osteosarcoma cell line), i.e. mitochondria devoid of DNA [59] raises some questions. These mitochondria possess ATP synthase complexes at levels comparable to those of the parent cells, but these complexes are peculiar since they lack the subunits encoded by the mitochondrial genome, a and A6L [324] (equivalent to subunits 6/a and 8 of yeast, respectively). Proponents of the rival c-ring model have been quick to point out [3, 325, 326] that at least subunit a is involved in dimerization [327] . Wittig and coworkers [327] , who also used osteosarcoma cells, have reported however that dimers and higher-order oligomers of the ATP synthase do form also in Rho0 cells, although at low levels because of their apparent destabilization. In fact, other subunits of the F O sector, in particular e and g (see above), are known to participate in dimerization. It may be mentioned that the opening of just one mPTP in a mitochondrion would be sufficient to cause a full-blown mPT. Furthermore, it may be reasonably argued that destabilized dimers might form the mPTP more readily than WT ones. Indeed, Rho0 mitochondria were markedly susceptible to mPT induction, a behavior Masgras et al. tentatively attributed to the low transmembrane potential they maintain [59] .
mPTP formation by the c-ring of F O F 1 ATP synthase
The ATP synthase complex comprises what looks even at a superficial sight like a ready-made membrane-spanning channel, namely the membrane-embedded ring of c subunits (the "c-ring") detached from the F 1 sector. This portion of the complex thus became a candidate to the role of pore former. In 2000 McGeogh et al. [328] had reported it can form a cation-selective, Ca 2+ -inhibited channel. In
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-and calmodulin-dependent pore formation by the V 0 sector of yeast vacuolar ATPase was reported by Peters et al. [329] . More recently, Alavian et al. [330] have observed that upon reconstitution into an artificial bilayer assemblies of tagged c subunits of the F O formed large, unselective, CsA-and Ca
-insensitive pores at least superficially resembling those of the mPTP (for a discussion of the differences between the results of these authors and those of [328] see: [331] ). Pore conductance was reportedly decreased by addition of the F 1 ß subunit, an effect which might actually have low relevance (for a discussion see [1] ). The biochemical data presented suggest that the material incorporated into the bilayer as oligomers formed by approximately 16 monomers, a high stoichiometry (apparent oligomer mass~250 kDa; apparent monomer mass:~15 kDa; as pointed out by Halestrap [4, 332] the MW of the mature subunit ought to be 7.6 kDa), presumably arranged to form a "barrel" or annular structure [333] . The material utilized was isolated from HEK 293T cells transfected with the tagged hATP5G1 subunit DNA. The authors did not mention any toxic effects linked to the expression of their construct. Patch-clamping mitochondria or sub-mitochondrial vesicles (SMV; inverted IMM vesicles containing F O F 1 ATPase) showed channel activity which was inhibited by CsA. Infrequent CypD-enhanced, CsA-inhibited channel activity was observed also upon reconstitution of purified monomeric ATPase. The effect of CsA disappeared if the SMV had been exposed to urea, a denaturing agent known to cause detachment of the F 1 portion. This observation implies that CsA-sensitive megachannels could be formed also in the presence of a still-connected F 1 . Whether treatment with urea induced a marked increase in the density of operating megachannels in the SMV membranes, as may be expected in the framework of this model, was not reported. When engineered c subunit constructs were expressed to take advantage of the FlAsh methodology to follow protein-protein interactions, the fluorescence readout indicated that CsA caused a closer packing together of c subunits. Addition of the Ca 2+ ionophore ionomycin (i.e., cellular and mitochondrial Ca 2+ increase) had the opposite effect, and this was antagonized by CsA. The authors chose to interpret these observations in terms of Ca 2+ -induced, CsA-antagonized c-ring-pore opening. In particular, CsAinduced fluorescence increase in untreated cells was taken to suggest channel inhibition. Since however it is difficult to think that the cells could survive with even a few operating pores, another, more prudent interpretation may be that Ca 2+ or CsA-induced structural changes of the (dimeric?) ATPase complex are reflected also at the level of the c-ring, without necessarily implying opening or closing of a c-ring pore. Again, since the CypD binding site is located in the F 1 portion, sensitivity to CypD implies the presence of F 1 and its continuing interaction with the c-ring. This is supported by a study by the same group [334] in which dexpramipexole, a neuroprotective drug, was found to: i) bind to purified OSCP and b components of the ATPase; ii) reduce the amplitude of currents flowing through the membrane of brain-derived SMVs (see also [335] ). Interestingly, the effect of dexpramipexole would seem to be a concentration-dependent decrease of pore conductance, rather than an alteration of its open probability. Detachment of the F 1 component by urea treatment did not have much of an effect on the conductance of membrane patches, but it eliminated the inhibitory effect of the drug [334] . In another experiment reported by Alavian et al. [330] endogenous c subunit expression was decreased with shRNA and the efflux of calcein from mitochondria was followed as an indication of the occurrence of the permeability transition, following the method developed by Petronilli et al. [336] . Downregulating subunit c expression resulted in repression of mitochondrial calcein efflux, i.e., of permeability transition onset. This observation can however be accounted for by either one of the models we are discussing, as one would definitely expect repression of the c-ring building blocks to have an impact on the assembly of the whole F O sector and quite possibly on ATPase dimer/oligomer formation, or else to result in a lower density of normally assembled complexes. Indeed, these cells could not survive in the absence of glucose. These aspects apparently were not investigated. In another test of their views, Alavian et al. [330] produced four variant c subunits containing a glycine-to-valine mutation expected to loosen the packing of the "staves" in the c-ring "barrel", and duly observed an (enormous) increase of pore conductance upon reconstitution of the purified proteins. These mutated c subunits could not rescue cells in which the endogenous c protein had been silenced and which had been placed in a galactose medium. Again, however, this only means that a functional c-ring is needed for the well-being of cells relying on oxidative phosphorylation.
In a similar study Azarashvili and coworkers [337] used native subunit c isolated from Rat Liver Mitochondria (RLM) (by chloroform/ methanol extraction) or from storage bodies from ceroid lipofuscinosis. Based on the groups' previous studies [292] [293] [294] , dephosphorylation of subunit c was procured by inducing the mPT before isolation of the protein. The non-(or less-) phosphorylated form lowered the Ca 2+ threshold of CsA-sensitive permeabilization of the IMM of isolated mitochondria. When added to planar lipid membranes both preparations of protein induced electrical activity with conductance variations of a variety of magnitudes, including very large ones (up to 2 nS in 50 mM NaCl).
The issue of c-ring involvement in the mPTP has also been tackled by Paolo Pinton's group, adopting a cellular biochemistry approach [325] . Using siRNAs and/or transfection with tagged ATPG1 DNA they induced depletion of endogenous c subunit or overexpression of the tagged one in HeLa cells. Whether depletion or overexpression of the c subunit was accompanied by corresponding variations in the expression of other ATP synthase subunits and fully assembled complexes, or in the oligomeric organization of the ATPase, was not reported. It seems at any rate likely that depletion results in a lower number of full and functional F O F 1 assemblies being created, since a decreased c monomer stoichiometry in a ring would presumably result in a narrower lumen, which may find it difficult to accommodate the connecting γ-subunit shaft despite its elasticity [338] . Depletion did not affect mitochondrial ATP levels, coherently with the reliance of these cells on glycolysis (studies in a galactose-based medium were not reported). Perhaps surprisingly, overexpression of the subunit determined a stronger increase, with respect to control cells, of mtATP levels in response to histamine stimulation and consequent mitochondrial Ca 2+ increase. At the same time the transmembrane potential (Δ ψ m ), as measured by the tetra methyl Rhodamine (TMR) fluorescence method, was found to decrease, a surprising observation unless a compensating ΔpH increase also occurred, which is likely but was not reported. When mitochondrial Ca 2+ increase was induced by administration of ionomycin, c subunit-depleted cells turned out to be more resistant, and conversely c subunitoverexpressing cells less resistant, to CsA-inhibitable IMM permeabilization (as assessed by the calcein-Co 2+ assay). Analogously, the intensity and kinetics of the noxious effects of intensive oxidative stress (H 2 O 2 ) or glutamate (on cultured, oxphos-relying neurons) were positively correlated to the expression levels of subunit c. The model supported by these groups tentatively envisions F 1 -detached F O sectors as the core solute-transporting unit of the mPTP. In the current version, detachment does not need to be complete: "unplugging" may be partial, or the F 1 complex may remain in the immediate vicinity of the c-ring, possibly due to continuing interaction with the peripheral stalk. Unbinding/binding of F 1 would determine pore activation or inactivation, respectively, while "c-barrel breathing" may account for faster time-scale conductance variations [2, 334] . This model is elastic enough to allow the vision that the two rival models may merge into one: in ATPase dimers, but not monomers, stimuli may be conducted from the F 1 portion to the membrane-embedded c-ring(s) determining a loosening up of the structure and pore formation. The complex pharmacology of the mPTP furthermore practically demands that the ATPase interact with regulatory components such as the ANT (e.g. [2] [3] [4] 270, 271, 339] ). The emergence of the c-ring model calls new attention to the mPTP-inhibitory effect of oligomycin (for ref., e.g., [11] ). This macrolide binds at the interface between c and a subunits [308, 340] . Its effects on mPT onset had been attributed to the increase in Δψ m it causes by blocking ATP but a structural effect is now a possibility.
SPG7
A recent paper [235] aims to breathe new life into the formerly popular tripartite model envisioning mPTP formation by a complex of a regulatory mitochondrial matrix protein (CypD), an IMM protein (the ANT or other mitochondrial carrier) and an OMM protein (VDAC). In this new edition however the IMM component is not provided by a solute carrier, but by SPG7 (spastic paraplegia 7; paraplegin) (Fig. 2B) . The key observation is that knock-down (KD) or knock-out (KO) of SPG7 renders mitochondria more resistant to Ca 2+ -induced mPT, as assessed mainly by the CRC assay using permeabilized cells. SPG7 is an AAA-type protease involved in processing other mitochondrial proteins ( [341] ; for reviews on mitochondrial AAA proteases: [342] [343] [344] [345] ). To our knowledge AAA ATPases have not been reported to form permanent pores, but many members of the superfamily function as chaperoning (e.g. [346] ), protein-transporting (e.g. [347, 348] ) or DNA-processing (e.g. [349] ) oligomeric (normally hexameric) ringshaped "nanomachines" in which the polymer is believed to be threaded through a central cryptic channel (e.g. [350] [351] [352] .
Another AAA ATPase closely related to SPG7, AFG3 (AFG3L2 in humans [353] ; AFG3L1 & 2 in mouse [354] ) is located in the IMM of metazoans and forms variable-composition heterooligomers with SPG7 (or, in its absence, homooligomers) [355, 356] . These oligomers are thought to constitute the mitochondrial AAA protease (mAAAp) involved -along with other proteases such as Bcs1 (e.g. [357] ), YME1L1 (e.g. [358] ) and OMA1 [359] -in the processing and quality control of a variety of mitochondrial proteins, including subunits of the respiratory chain [360, 361] . In fact, one of the mAAAp-dependent processes is the correct assembly of mitochondrial ribosomes [361] [362] [363] .
Loss or mutations of SPG7 or AFG3L2 are associated with respiratory chain deficiencies, in particular at Complex I [355, 361, 364, 365] , multiple mt DNA deletions [366, 367] , increased mt ROS production [368] and sensitivity to oxidative stress [355] . Shanmughapriya et al. [235] do not report assessing ROS production in cells KD or KO for SPG7. It should be pointed out however that an increased ROS production consequent to SPG7 deficiency would be predicted to facilitate, if anything, the onset of the permeability transition, while the opposite was observed in SPG7-KD/KO cells. Some data reported in Shanmughapriya et al. [235] hint that something may be amiss with the mitochondrial respiratory chain in SPG7-KD cells: the NADH/NAD + ratio was much higher than in control cells (both without and with rotenone, the Complex I inhibitor), and so was the oxygen consumption rate (OCR) even though cellular ATP levels were also higher. A relationship between complex I functionality and the mPTP has long been recognized, even though its nature has not yet been fully clarified [247, 289, 290, 369] . According to Maltecca et al. [370] , another consequence of m-AAA protease (the AFG3L2 component, in the study) deficiency is impaired Ca 2+ uptake into mitochondria. Defective mitochondrial Ca 2+ uptake, while presumably noxious for the cell, would be expected to antagonize the onset of the mPT, as observed upon SPG7 knock-down. However the tracings presented in Shanmughapriya et al. [235] do not suggest any gross alteration of uptake kinetics or of extramitochondrial Ca 2+ levels up to the point of Ca 2+ release.
The candidacy of SPG7 emerged from an initial screening in which 128 possibly relevant genes were knocked down by expression of an appropriate shRNA, and the effect of this manipulation on the CRC and Ca
2+
-induced depolarization of mitochondria was evaluated. The gene panel included some much-discussed earlier candidates to the role of core mPTP components: SLC25A5 (ANT2, one of the isoforms of the adenine nucleotide exchanger), SLC25A3 (Pi carrier), a number of other IMM transporters, VDAC1, two subunits (f and g) of the F O sector of the mitochondrial F O F 1 ATPase. Notably, the other variants of the adenine nucleotide exchanger and the c subunit of F O or other complex V subunits were not tested, perhaps for practical reasons. The strongest, and comparable, improvements in CRC were observed upon KD of cyclophilin D, SLC25A5 (ANT2), SLC25A30 (KMCP1, a renal mitochondrial carrier [371] ), CCDC58 (alias CG15881; mitochondrionassociated, undefined function [372] ), SPG7, C10orf10 (DEPP; peroxisomal and mitochondrial, possibly involved in regulation of ROS signalling [373] and in autophagy [374] ), C6orf203 (an uncharacterized mitochondrial protein [375] ), C18orf19 (alias FAM210A; a mitochondrial uncharacterized protein), PMPCA (α-MPP; mitochondrial processing peptidase [376] ), CHCHD3 (Mic19; a component of the mitochondrial contact site and cristae organizing system [377] ), MAVS (mitochondrial antiviral signaling protein; [378] ). The list clearly signals the possibility of indirect effects, e.g. in the case of PMPCA. The average increase in the number of Ca 2+ pulses needed to elicit IMM permeabilization upon KD of these genes was by a factor of 2.2 ± 0.1. KD of AFG3L2 or VDAC1 had a more modest effect (a factor of 1.5 ± 0.1). It should be pointed out that in all cases Ca 2+ -inducedCa 2+ release and membrane depolarization eventually occurred.
SPG7 was singled out for further study because SPG7-Flag constructs co-immunoprecipitated with CypD-HA constructs, demonstrating an interaction (confirmed by other experiments) which is generally considered to be an hallmark of the permeability transition pore. None of the "flagged" constructs derived from the other candidates behaved analogously. It may be pointed out that in this study no evidence for such an interaction was obtained even in the case of the adenine nucleotide carrier (ANT2) and of the phosphate carrier. CypD-ANT [231, 232, 379, 380] and CypD-PiC [216, 233, 381] interactions have been reported, although Halestrap's group eventually considered that their evidence for CypD-ANT binding may have been an artifact [233] . Those studies were carried out with rat material (liver mitochondria, which express both ANT1 and, mainly, ANT2 [233, 382] ), while Shanmughapriya et al. performed their essays in a human cell line (HEK293). The aminoacidic sequences of rat/human ANT1/2 (4 proteins) are at least 89% identical (pairwise comparisons; at least 94% if conservative mutations are also considered), including conserved Cysteins at positions 57, 160 and 257, which have been proposed to modulate CypD binding [383] . For PiC the identity between rat and human forms is 88% (93%). It seems therefore unlikely, although it's not ruled out, that this discrepancy with the earlier reports may be due to an interspecies difference. Furthermore, CsA sensitivity of the mPT has been documented in both rat and human cells (e.g. for the latter: [384] ). It may be mentioned here that CypD has been reported to interact, under appropriate circumstances, with several other proteins, including mitochondrial transcription factors B1, B2 (TFB2M) [385] and PPARα [386] ), Hsp90 and TRAP-1 [162] , ERK2 and GSK-3 [241] , Bcl-2 [387] , OSCP [302, 388] , p53 (e.g. [389, 390] ), 2′,3′-cyclic nucleotide 3′-phosphodiesterase (CNP) [391] , SIRT3 [101] , mammalian sterile 20-like kinase 1 (MST1) [392] , DnaJC15 [393] .
The results of Shanmughapiya and coworkers thus contribute to the current scepticism regarding the role of mitochondrial carriers in the mPT. This scepticism however extends also to the participation of VDACs [218] [219] [220] , while Shanmughapiya et al. propose that VDAC1 is a component of the mPTP complex. Again this tentative conclusion is based on protein-protein interaction assays: VDAC1 and SPG7 were pulled down together by an HA Ab from lysates of COS-7 cells (a monkey line) expressing either SPG7-HA or VDAC1-HA and the FLAGged counterpart. Remarkably, IP of VDAC1-HA also pulled down SLC25A30 (an IMM carrier) and the GBAS product (alias Protein NipSnap homolog 2, an OMM resident protein), but not CypD, despite its avowed interaction with SPG7 (AFG3L2 is not mentioned in this context). VDAC has been reported to interact with a number of proteins (rev: [394] ). Apparently the reason Shanmughapiya et al. have for proposing that the interaction with SPG7 is relevant for the mPT is that the CRC was (modestly) increased by expression of a ΔS1-SPG7 mutant which was unable to bind to VDAC1, while there was no such increase upon expression of a ΔS2-SPG7 mutant which was still able to bind to VDAC1. The effect on CRC of a third mutant, ΔS3-SPG7, which was also unable to bind to VDAC1, was not reported. The effects of these deletions on SPG7 structure or properties and the possibility that factors other than VDAC1 binding may have been involved apparently were not investigated. It may be worth recalling here that the model envisioning the mPTP as a complex of the ANT, CypD, VDAC (and others) also originated from experiments indicating an interaction among these proteins [395] [396] [397] . In our opinion the participation of VDAC to mPTP complex formation thus remains very doubtful, given also the modest effect of its KD on the CRC.
Other details suggest caution in concluding that SPG7 is a core component of the mPTP. Shanmughapiya et al. mention unpublished results indicating that overexpression of SPG7 did not increase susceptibility to the Ca 2+ -induced mPT. Knock-down of either cyclophilin D or SPG7 had much the same effect in various experiments (e.g. ionomycin-and H 2 O 2 -induced release of preloaded calcein from mitochondria); since cyclophilin D is generally thought of as a regulator of the mPTP, rather than as a necessary component, this leaves the possibility open that SPG7 may also have a regulatory role. Indeed, Ca 2+ -induced Ca 2+ release and depolarization eventually occur in SPG7-KO cells, just as they eventually happen in CypD-less cells. However, conceivably AFG3L2 may substitute for the missing SPG7 as a participant in the permeability transition, much as it can do for other functions. A definite word on the role of mAAAp in the mPT may, again, come from the combination of genetic and electrophysiological approaches. Shanmughapiya et al. report patch-clamping mitoplasts from SPG7-or CypD-KD cells, but the experiments only aimed at checking whether the knock-down of these proteins altered the mitochondrial Ca 2+ transport apparatus (which it didn't). A characterization of Ca 2+ -induced, CsA-sensitive, high-conductance pore activity in SPG7-and AFG3L2-depleted mitoplasts seems warranted. Conversely, a study of SPG7-AFG3L2 complexes incorporated into artificial membranes may provide valuable information.
Finally, we ask to be forgiven for calling the attention of mPT aficionados to a specific experiment by Shanmughapiya et al. Ca 2 + pulses were delivered to cells until coincident Ca 2 + -induced Ca 2 + -release and depolarization were elicited. Addition of Ru360
(an MCU inhibitor; (e.g. [398, 399] ) soon after the onset of these phenomena induced re-polarization, which was only hinted at if the inhibitor was added later. We offer the following interpretation: Ca , leading to a new opening of the mPTP. After a few such cycles the mitochondrion will have lost most of the small molecules needed for respiration (NADH, Krebs cycle intermediates etc.), and will not be able to repolarize anymore. However, if Ru360 is provided before this happens, Ca 2+ uptake by repolarized mitochondria will be blocked, the mitochondria will not undergo the mPT anew, and the eventual population-wide result will be persistent repolarization. This behaviour thus may constitute circumstantial further evidence for the reversibility of mPTP opening in situ. The effect of Ru360-containing Ruthenium Red on the course of Ca
-induced Ca 2+ release had already been used in the '80s by Pfeiffer's group to desume that isolated mitochondria formed heterogenous populations of organelles with different propensities to undergo the PT: Ca 2+ released by the "weaker" mitochondria, taken up by the more resistant ones, induces the mPT in the latter, and so forth. Progression of the mPT throughout the population could be stopped by inhibiting Ca 2+ uptake [400, 401] .
Conclusion
We began this review mentioning the Mahābhārata and the Divine Comedy. We may end it echoing the great Greek epics, the Iliad and the Odyssey: the clash of opposite camps, the long journey of travelers buffeted by storms, distracted by sirens and nymphs, obfuscated by lotus fruits, harassed by cyclops and frowning divinities. Are we seeing Ithaca, or is it only Cephalonia? We can't be too far, anyhow.
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